Multi-million-dollar investments by Anges will help Vasomune progress its peptide-based therapy for blood vessel-related diseases to the clinic.
Vasomune Theraueptics, a Canada-based critical care peptide spinout from Sunnybrook Research Institute (SRI) and commercialisation firm Mars Innovation, has secured multi-million-dollar commitments from biotherapeutics manufacturer Anges.
The commitments are part of a co-development partnership between the pair focused on treating blood vessel-related diseases with Vasomune’s peptide-based Tie2 receptor agonist, branded Vasculotide.
Anges will provide Vasomune with upfront and clinical milestone payments. Both parties will equally share all expenses and proceeds, including those resulting from any third-party licensing agreement.
The partners are initially targeting a human proof-of-concept for using Vasculotide to treat acute respiratory distress syndrome (ARDS), a life-threatening condition in which the lungs are unable to provide other vital organs with enough oxygen.
Clinical trials on ADRS are scheduled for 2020. Tie2’s underlying thesis could be repurposed to provide therapies for other critical care complications such as asthma, atopic dermatitis, glaucoma and the vascular effects of diabetes.
Vasculotide was formulated…
